Article
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.
Breast cancer research : BCR - 1 Jan 2009
Puppe Julian, Drost Rinske, Liu Xiaoling, Joosse Simon A, Evers Bastiaan, Cornelissen-Steijger Paulien, Nederlof Petra, Yu Qiang, Jonkers Jos, van Lohuizen Maarten, Pietersen Alexandra M
Abstract excerpt
INTRODUCTION: Treatment of breast cancer is becoming more individualized with the recognition of tumor subgroups that respond differently to available therapies. Breast cancer 1 gene (BRCA1)-deficient tumors are usually of the basal subtype and associated with poor survival rates, highlighting the need for more effective therapy. METHODS: We investigated a mouse model that closely mimics breast cancer arising in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.